Your browser doesn't support javascript.
loading
Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-É£ Enzyme-Linked ImmunoSpot (ELISpot) protocols.
Waerlop, Gwenn; Leroux-Roels, Geert; Pagnon, Anke; Begue, Sarah; Salaun, Bruno; Janssens, Michel; Medaglini, Donata; Pettini, Elena; Montomoli, Emanuele; Gianchecchi, Elena; Lambe, Teresa; Godfrey, Leila; Bull, Maireid; Bellamy, Duncan; Amdam, Håkon; Bredholt, Geir; Cox, Rebecca Jane; Clement, Frédéric.
Afiliação
  • Waerlop G; Center for Vaccinology (CEVAC), Ghent University and University Hospital, Ghent, Belgium. Electronic address: Gwenn.Waerlop@UGent.be.
  • Leroux-Roels G; Center for Vaccinology (CEVAC), Ghent University and University Hospital, Ghent, Belgium.
  • Pagnon A; Sanofi, Research Global Immunology, Marcy l'Etoile, France.
  • Begue S; Sanofi, Research Global Immunology, Marcy l'Etoile, France.
  • Salaun B; GSK, Rixensart, Belgium.
  • Janssens M; GSK, Rixensart, Belgium.
  • Medaglini D; Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
  • Pettini E; Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
  • Montomoli E; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy; VisMederi srl, 53100 Siena, Italy.
  • Gianchecchi E; VisMederi srl, 53100 Siena, Italy.
  • Lambe T; Oxford Vaccine Group, Department of Paediatrics, Medical Sciences Division, University of Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, United Kingdom.
  • Godfrey L; Oxford Vaccine Group, Department of Paediatrics, Medical Sciences Division, University of Oxford, UK.
  • Bull M; Oxford Vaccine Group, Department of Paediatrics, Medical Sciences Division, University of Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, United Kingdom.
  • Bellamy D; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Amdam H; Influenza Centre, Department of Clinical Science, University of Bergen, N5021 Bergen, Norway.
  • Bredholt G; Influenza Centre, Department of Clinical Science, University of Bergen, N5021 Bergen, Norway.
  • Cox RJ; Influenza Centre, Department of Clinical Science, University of Bergen, N5021 Bergen, Norway.
  • Clement F; Center for Vaccinology (CEVAC), Ghent University and University Hospital, Ghent, Belgium.
J Immunol Methods ; 523: 113584, 2023 12.
Article em En | MEDLINE | ID: mdl-37918618
ABSTRACT
The magnitude and quality of cell-mediated immune responses elicited by natural infection or vaccination are commonly measured by Interferon-É£ (IFN-É£) Enzyme-Linked ImmunoSpot (ELISpot) and Intracellular Cytokine Staining (ICS). To date, laboratories apply a variety of in-house procedures which leads to diverging results, complicates interlaboratory comparisons and hampers vaccine evaluations. During the FLUCOP project, efforts have been made to develop harmonized Standard Operating Procedures (SOPs) for influenza-specific IFN-É£ ELISpot and ICS assays. Exploratory pilot studies provided information about the interlaboratory variation before harmonization efforts were initiated. Here we report the results of two proficiency tests organized to evaluate the impact of the harmonization effort on assay results and the performance of participating FLUCOP partners. The introduction of the IFN-É£ ELISpot SOP reduced variation of both background and stimulated responses. Post-harmonization background responses were all lower than an arbitrary threshold of 50 SFU/million cells. When stimulated with A/California and B/Phuket, a statistically significant reduction in variation (p < 0.0001) was observed and CV values were strongly reduced, from 148% to 77% for A/California and from 126% to 73% for B/Phuket. The harmonizing effect of applying an ICS SOP was also confirmed by an increased homogeneity of data obtained by the individual labs. The application of acceptance criteria on cell viability and background responses further enhanced the data homogeneity. Finally, as the same set of samples was analyzed by both the IFN-É£ ELISpot and the ICS assays, a method comparison was performed. A clear correlation between the two methods was observed, but they cannot be considered interchangeable. In conclusion, proficiency tests show that a limited harmonization effort consisting of the introduction of SOPs and the use of the same in vitro stimulating antigens leads to a reduction of the interlaboratory variation of IFN-É£ ELISpot data and demonstrate that substantial improvements for the ICS assay are achieved as comparable laboratory datasets could be generated. Additional steps to further reduce the interlaboratory variation of ICS data can consist of standardized gating templates and detailed data reporting instructions as well as further efforts to harmonize reagent and instrument use.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana Limite: Humans Idioma: En Revista: J Immunol Methods Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana Limite: Humans Idioma: En Revista: J Immunol Methods Ano de publicação: 2023 Tipo de documento: Article